Vitória Adrielly Catschor dos Santos

Mrs. Vitória Adrielly Catschor dos Santos


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
NONatasha de Oliveira
Natasha de Oliveira
FSFrancisco Denis Souza Santos
Francisco Denis Souza Santos
VSVitória Adrielly Catschor dos Santos
Vitória Adrielly Catschor dos Santos
MMMara Maia
Mara Maia
TThaís Oliveira
Thaís Oliveira
ODOdir Dellagostin
Odir Dellagostin
The first leptospiral recombinant vaccine was developed in the late 1990s. Since then, progress in the fields of reverse vaccinology (RV) and structural vaccinology (SV) has significantly improved the identification of novel surface-exposed and conserved vaccine targets. However, developing recombinant vaccines for leptospirosis faces various challenges, including selecting the ideal expression platform or delivery system, assessing immunogenicity, selecting adjuvants, establishing vaccine formulation, demonstrating protective efficacy against lethal disease in homologous challenge, achieving full renal clearance using experimental models, and reproducibility of protective efficacy against heterologous challenge. In this review, we highlight the role of the expression/delivery system employed in studies based on the well-known LipL32 and leptospiral immunoglobulin-like (Lig) proteins, as well as the choice of adjuvants, as key factors to achieving the best vaccine performance in terms of protective efficacy against lethal infection and induction of sterile immunity.